Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Prasterone (Primary)
- Indications Decreased libido
- Focus Therapeutic Use
- Sponsors Endoceutics
- 31 Oct 2017 Status changed from not yet recruiting to recruiting.
- 02 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
- 22 Sep 2017 New trial record